Literature DB >> 6691882

Prediction of response to theophylline in chronic bronchitis.

B Whiting, A W Kelman, A D Struthers.   

Abstract

In chronic bronchitis, intersubject variability in both theophylline pharmacokinetics and pharmacodynamics must be taken into account if the drug is to be used to its best advantage. Both kinds of variability can be integrated into a model which relates the steady state concentration of theophylline to simultaneously measured ventilatory response (most conveniently, the FVC). In a group of 56 patients with chronic bronchitis, the mean +/- s.d. linear response to increasing steady state concentrations of theophylline was 0.04 +/- 0.012 1 microgram-1 ml, starting from a mean +/- s.d. pretreatment FVC of 1.58 +/- 0.791. Using these population parameter values, with or without a pretreatment FVC and/or one steady state concentration -FVC observation, it was possible to predict the degree of response which would be achieved by a smaller group of 20 similar patients. These estimates were obtained using a mathematical procedure based on Bayesian Probability Theory and Maximum Likelihood Estimation. Estimates of the overall response in individual patients allowed prediction of the response at any steady state concentration. These estimates were unbiased and accurate enough for clinical use when they were based on a pretreatment FVC and/or one paired steady state concentration -FVC observation.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6691882      PMCID: PMC1463311          DOI: 10.1111/j.1365-2125.1984.tb04990.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  11 in total

1.  Forecasting individual pharmacokinetics.

Authors:  L B Sheiner; S Beal; B Rosenberg; V V Marathe
Journal:  Clin Pharmacol Ther       Date:  1979-09       Impact factor: 6.875

2.  OPT: a package of computer programs for parameter optimisation in clinical pharmacokinetics.

Authors:  A W Kelman; B Whiting; S M Bryson
Journal:  Br J Clin Pharmacol       Date:  1982-08       Impact factor: 4.335

Review 3.  The modelling of drug response.

Authors:  B Whiting; A W Kelman
Journal:  Clin Sci (Lond)       Date:  1980-11       Impact factor: 6.124

Review 4.  Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models.

Authors:  N H Holford; L B Sheiner
Journal:  Clin Pharmacokinet       Date:  1981 Nov-Dec       Impact factor: 6.447

5.  Quantitative analysis of the disopyramide concentration-effect relationship.

Authors:  B Whiting; N H Holford; L B Sheiner
Journal:  Br J Clin Pharmacol       Date:  1980-01       Impact factor: 4.335

6.  Some suggestions for measuring predictive performance.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1981-08

7.  Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharm Sci       Date:  1982-12       Impact factor: 3.534

8.  Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine.

Authors:  L B Sheiner; D R Stanski; S Vozeh; R D Miller; J Ham
Journal:  Clin Pharmacol Ther       Date:  1979-03       Impact factor: 6.875

9.  Dyspnoea, disability, and distance walked: comparison of estimates of exercise performance in respiratory disease.

Authors:  C R McGavin; M Artvinli; H Naoe; G J McHardy
Journal:  Br Med J       Date:  1978-07-22

10.  Modelling theophylline response in individual patients with chronic bronchitis.

Authors:  B Whiting; A W Kelman; J Barclay; G J Addis
Journal:  Br J Clin Pharmacol       Date:  1981-10       Impact factor: 4.335

View more
  3 in total

Review 1.  Bayesian parameter estimation and population pharmacokinetics.

Authors:  A H Thomson; B Whiting
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

Review 2.  Pharmacokinetic-pharmacodynamic modelling as applied to bronchial asthma.

Authors:  R P Koopmans; R E Jonkers; M C Braat; C J van Boxtel
Journal:  Clin Pharmacokinet       Date:  1995-10       Impact factor: 6.447

Review 3.  Theophylline in the management of airflow obstruction. 1. Much evidence suggests that theophylline is valuable.

Authors:  G J Addis
Journal:  BMJ       Date:  1990-04-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.